Emergence of fluoroquinolone-resistant tuberculosis in New York City

E. A. Sullivan; L. Palumbo; A. Ebrahimzadeh; T. R. Frieden; E. A. Sullivan; T. R. Frieden; B. N. Kreiswirth; V. Kapur; J. M. Musser

doi:10.1016/S0140-6736(95)90980-X

Emergence of fluoroquinolone-resistant tuberculosis in New York City

E. A. Sullivan
, L. Palumbo
, A. Ebrahimzadeh
, T. R. Frieden
, E. A. Sullivan
, T. R. Frieden
, B. N. Kreiswirth
, V. Kapur
, J. M. Musser

New York City Department of Health and Mental Hygiene
Centers for Disease Control and Prevention
Baylor College of Medicine

Research output: Contribution to journal › Article › peer-review

121 Scopus citations

Abstract

22 patients infected with fluoroquinolone-resistant Mycobacterium tuberculosis in New York City were identified between January, 1991, and November, 1993. In 16 patients resistance arose as a result of inadequate or inappropriate treatment. 6 patients had primary infection with fluoroquinolone-resistant organisms; 5 acquired the organisms nosocomially. Seven distinct patterns of restriction-fragment length polymorphism were identified in isolates from 21 patients. Fluoroquinolones should be restricted to patients with multidrug-resistant disease or intolerance to other antituberculosis drugs. All patients with multidrug-resistant tuberculosis should be on directly observed therapy.

Original language	English
Pages (from-to)	1148-1150
Number of pages	3
Journal	The Lancet
Volume	345
Issue number	8958
DOIs	https://doi.org/10.1016/S0140-6736(95)90980-X
State	Published - 6 May 1995

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/S0140-6736(95)90980-X

Cite this

@article{d4096287808f4d8792ff391fe9b1eff8,

title = "Emergence of fluoroquinolone-resistant tuberculosis in New York City",

abstract = "22 patients infected with fluoroquinolone-resistant Mycobacterium tuberculosis in New York City were identified between January, 1991, and November, 1993. In 16 patients resistance arose as a result of inadequate or inappropriate treatment. 6 patients had primary infection with fluoroquinolone-resistant organisms; 5 acquired the organisms nosocomially. Seven distinct patterns of restriction-fragment length polymorphism were identified in isolates from 21 patients. Fluoroquinolones should be restricted to patients with multidrug-resistant disease or intolerance to other antituberculosis drugs. All patients with multidrug-resistant tuberculosis should be on directly observed therapy.",

author = "Sullivan, \{E. A.\} and L. Palumbo and A. Ebrahimzadeh and Frieden, \{T. R.\} and Sullivan, \{E. A.\} and Frieden, \{T. R.\} and Kreiswirth, \{B. N.\} and V. Kapur and Musser, \{J. M.\}",

year = "1995",

month = may,

day = "6",

doi = "10.1016/S0140-6736(95)90980-X",

language = "English",

volume = "345",

pages = "1148--1150",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "8958",

}

TY - JOUR

T1 - Emergence of fluoroquinolone-resistant tuberculosis in New York City

AU - Sullivan, E. A.

AU - Palumbo, L.

AU - Ebrahimzadeh, A.

AU - Frieden, T. R.

AU - Sullivan, E. A.

AU - Frieden, T. R.

AU - Kreiswirth, B. N.

AU - Kapur, V.

AU - Musser, J. M.

PY - 1995/5/6

Y1 - 1995/5/6

N2 - 22 patients infected with fluoroquinolone-resistant Mycobacterium tuberculosis in New York City were identified between January, 1991, and November, 1993. In 16 patients resistance arose as a result of inadequate or inappropriate treatment. 6 patients had primary infection with fluoroquinolone-resistant organisms; 5 acquired the organisms nosocomially. Seven distinct patterns of restriction-fragment length polymorphism were identified in isolates from 21 patients. Fluoroquinolones should be restricted to patients with multidrug-resistant disease or intolerance to other antituberculosis drugs. All patients with multidrug-resistant tuberculosis should be on directly observed therapy.

AB - 22 patients infected with fluoroquinolone-resistant Mycobacterium tuberculosis in New York City were identified between January, 1991, and November, 1993. In 16 patients resistance arose as a result of inadequate or inappropriate treatment. 6 patients had primary infection with fluoroquinolone-resistant organisms; 5 acquired the organisms nosocomially. Seven distinct patterns of restriction-fragment length polymorphism were identified in isolates from 21 patients. Fluoroquinolones should be restricted to patients with multidrug-resistant disease or intolerance to other antituberculosis drugs. All patients with multidrug-resistant tuberculosis should be on directly observed therapy.

UR - https://www.scopus.com/pages/publications/0029061114

U2 - 10.1016/S0140-6736(95)90980-X

DO - 10.1016/S0140-6736(95)90980-X

M3 - Article

C2 - 7723548

AN - SCOPUS:0029061114

SN - 0140-6736

VL - 345

SP - 1148

EP - 1150

JO - The Lancet

JF - The Lancet

IS - 8958

ER -

Emergence of fluoroquinolone-resistant tuberculosis in New York City

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this